MAYO 2019 

Harmful Medications Prescribed to Nearly 25% of Patients with HFrEF

A recent study published in the American Journal of Cardiology demonstrated that approximately 24% of patients with HF with reduced ejection fraction were prescribe a medication that could “potentially lead to or worsen HF as defined by current guidelines.” Potentially harmful drugs were identified as oral medications that could induce or precipitate HF based on a previous scientific statement from the American Heart Association which included diabetes medications, non-steroidal anti-inflammatory agents, antihypertensives, pulmonary medications, anti-arrhythmic medications and psychiatric and neurological medications. The study’s authors noted: “Adherence to the ACC/AHA guidelines and careful review of medication lists by prescribing physicians and especially cardiologists is crucial.”

Increased Arterial Stiffness Raises Stroke Risk in Type 2 Diabetes

Recent findings presented in Diabetic Medicine demonstrate that adults with type 2 diabetes who also  have stiffer arteries are more likely to experience stroke and vascular mortality than those without arterial stiffness. Researchers examined data from 1,910 adults with type 2 diabetes (mean age: 61 years; 30% women) who took part in the Second Manifestations of Arterial Disease (SMART) study at the University Medical Centre Utrecht in the Netherlands. The study’s authors commented, “People with type 2 diabetes are still at a markedly increased risk of (cardiovascular) mortality and morbidity. Part of this increased risk is thought to be explained by increased arterial stiffness, which is more prevalent in people with type 2 diabetes than those without diabetes.”

New insights on Link Between Lung Diseases and Cardiovascular Risk

According to a recent study published in the Journal of the American College of Cardiology, patients with common lung diseases are significantly more likely to develop cardiovascular disease. The study evaluated more than 1 million patients in England from 2000 to 2012, with results demonstrating independent associations between COPD and increased likelihood for ischemic heart disease. The study’s authors shared: “The most striking findings were that when compared to patients without lung disease, risk of ischemic heart disease was increased by 50% in asthmatics, 60% in fibrosis and 75% in COPD.”   

Common Food Additive Is Linked to Insulin Resistance

A preliminary study investigating the influence of a food additive called propionate on health found that consumption of propionate led to high blood sugar levels in the short term, and weight gain and insulin resistance in the long term. The food additive is widely used as a preservative in cheeses, baked goods, and artificial flavorings. A small trial involving humans found that those who consumed the additive experienced temporary increases in insulin resistance within a span of a few hours compared to those who had not consumed the additive. Researchers noted that additional research is needed before conclusive recommendations can be made.

FDA Expands Arrhythmia Indications for ECG Smartphone App

The FDA has provided AliveCor with two 510(k) clearances for its consumer ECG device. The technology (KardiaMobile) was previously cleared by the FDA to detect atrial fibrillation and normal sinus rhythm. Now, paired with an Apple Watch, the device can instantly analyze ECGs and detect an arrhythmia. In a statement to Cardiology Today, Chief Medical Officer of AliveCor, Jacqueline Shreibati, MD, commented: “The additional indications are for arrhythmias which are generally low risk and common in day-to-day life, and therefore provide necessary insights to patients and their doctors and will create a more informed dialogue between them.”
With dozens of recently released revised clinical guidelines, breakthrough trial data, and newly approved drugs on the market, it is increasingly important for clinicians leading the fight against cardiometabolic disease to review the latest topics and industry developments. Explore how the most respected leaders of the industry are advancing cardiometabolic health and combating the growing epidemic of cardiovascular diseases through sessions spotlighting the most recent and relevant research.
CMHC Faculty Members Discuss the Current State of  HFpEF Interventions
Mark your calendar: the 14th Annual Cardiometabolic Health Congress is right around the corner!
View this email in your browser

This is an email from Cardiometabolic Health Congress. 

Our mailing address is:
1801 N. Military Trail, Suite 200. Boca Raton, FL 33431
877.571.4700   •

Want to change how you receive these emails?
You are subscribed to this newsletter with the email address %user_email%.
To unsubscribe click here.